Get the Stockscreener App
7.59
4.17%
-0.33
After Hours:
7.90
0.31
+4.08%
Seres Therapeutics Inc stock is traded at $7.59, with a volume of 45,295.
It is down -4.17% in the last 24 hours and down -6.30% over the past month.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
See More
Previous Close:
$7.92
Open:
$7.85
24h Volume:
45,295
Relative Volume:
0.95
Market Cap:
$73.50M
Revenue:
$1.15M
Net Income/Loss:
$-46.90M
P/E Ratio:
-1.5125
EPS:
-5.0182
Net Cash Flow:
$-42.37M
1W Performance:
+2.02%
1M Performance:
-6.30%
6M Performance:
-55.01%
1Y Performance:
-1.04%
1-Day Range:
$7.41
$8.10
1-Week Range:
$7.41
$8.10
52-Week Range:
$6.5601
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
Name
Seres Therapeutics Inc
Sector
Industry
Phone
617 945 9626
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
7.59 | 76.70M | 1.15M | -46.90M | -42.37M | -5.0182 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-24-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-21-23 | Initiated | JP Morgan | Neutral |
| Jul-23-21 | Downgrade | Goldman | Neutral → Sell |
| May-18-21 | Resumed | Goldman | Neutral |
| Mar-05-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Sep-18-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-11-20 | Upgrade | Jefferies | Hold → Buy |
| Apr-30-19 | Initiated | Jefferies | Hold |
| Oct-22-18 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-17 | Initiated | Oppenheimer | Outperform |
| Aug-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-01-17 | Reiterated | FBR & Co. | Outperform |
| Aug-12-16 | Reiterated | FBR Capital | Outperform |
| Aug-01-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-01-16 | Reiterated | H.C. Wainwright | Buy |
| Jul-29-16 | Resumed | H.C. Wainwright | Buy |
| Mar-30-16 | Initiated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | Guggenheim | Buy |
| Jan-25-16 | Initiated | H.C. Wainwright | Buy |
| Oct-22-15 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-22-15 | Initiated | Canaccord Genuity | Buy |
| Jul-21-15 | Initiated | Goldman | Neutral |
| Jul-21-15 | Initiated | Leerink Partners | Outperform |
View All
Seres Therapeutics Inc Stock (MCRB) Latest News
MCRB SEC FilingsSeres Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Seres Therapeutics (MCRB) Q1 2026 Miss: What Went WrongEPS Surprise History - Newser
MCRB News | SERES THERAPEUTICS INC (NASDAQ:MCRB) - ChartMill
MCRB: AI-driven microbiome therapeutics pipeline advances toward key clinical and commercial milestones - TradingView
Teresa L. Young sells shares; MCRB (NASDAQ: MCRB) files Form 144 notice - Stock Titan
Officer at Seres Therapeutics (NASDAQ: MCRB) sells 79 shares under 10b5-1 tax plan - Stock Titan
Seres Therapeutics (MCRB) officer sells shares after RSU vesting under 10b5-1 plan - Stock Titan
Seres Therapeutics stock (US81750R1023): Q1 2026 results and private placement - AD HOC NEWS
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference - The Manila Times
How to watch Seres Therapeutics’ BioConnect investor presentation - Stock Titan
How Seres Therapeutics (MCRB) balances short term and long term focus | Q1 2026: EPS Misses ViewsNCAV - Newser
MSN Money - MSN
The working capital efficiency at Seres Therapeutics (MCRB) | Q1 2026: EPS Misses EstimatesProfit Margin - newser.com
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Seres Therapeutics 1Q 2026: Revenue $358K, EPS $(2.08) — 10-Q Summary - TradingView
Seres Therapeutics (NASDAQ: MCRB) Q1 2026 loss and going-concern risk - Stock Titan
Seres Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Seres Therapeutics (Nasdaq: MCRB) Q1 2026 results and cash runway - Stock Titan
Seres awaits SER-155 data in weeks with cash through Q3 - Stock Titan
Seres presents preclinical data on IBD drug candidate SER-603 - Investing.com UK
Seres presents preclinical data on IBD drug candidate SER-603 By Investing.com - Investing.com South Africa
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease - The Manila Times
Experimental IBD microbiome therapy earns DDW poster honor - Stock Titan
Seres Therapeutics Presents Preclinical Data at Digestive - GlobeNewswire
Seres Therapeutics Inc expected to post a loss of $1.88 a shareEarnings Preview - TradingView
MCRB stock declines as Seres Therapeutics pauses SER-155 phase 2 study and shrinks headcount by 30% - MSN
Seres Therapeutics (MCRB) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Nestlé Joins the Microbiome Therapeutics Innovation Group (MTIG); Krys Araujo‑Torres, MD, MPP to Represent Company - Yahoo Finance
Equity plan and director votes in Seres Therapeutics (NASDAQ: MCRB) 2026 proxy - Stock Titan
Microbiome Therapeutics Market is Going to Booming Growth - openPR.com
Chardan Capital Downgrades Seres Therapeutics (MCRB) - MSN
MCRB Price Today: Seres Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 200 Day Moving AverageHere's What Happened - MarketBeat
Seres Therapeutics (MCRB) Presents Key Data at ESCMID Congress - GuruFocus
Seres Therapeutics (MCRB) Showcases Research at ESCMID 2026 Cong - GuruFocus
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 - The Manila Times
Microbiome Therapeutics Market Size, Share | Forecast [2034] - Fortune Business Insights
Aug Catalysts: Is Seres Therapeutics Inc impacted by rising rates2026 AllTime Highs & Safe Entry Trade Signal Reports - baoquankhu1.vn
Seres Therapeutics Stock Price Drops Below 50-Day Average - National Today
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Seres Therapeutics Inc Stock (MCRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):